Ocuphire Pharma to Present at Two Investor Conferences in August

Rhea-AI Summary

Ocuphire Pharma (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company, has announced its participation in two upcoming investor conferences. Dr. George Magrath, the company's CEO, will present at:

1. The Canaccord Genuity 44th Annual Growth Conference in Boston, MA on August 14, 2024 at 9:00 a.m. ET in a fireside chat format.

2. The H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024 at 10:30 a.m. ET, delivering a presentation.

Ocuphire Pharma focuses on developing small-molecule therapies for retinal and refractive eye disorders. Company management will be available for one-on-one meetings during both conferences. Interested parties can contact their conference representative or email ir@ocuphire.com to arrange meetings.

FARMINGTON HILLS, Mich., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that George Magrath, M.D., M.B.A., M.S., Chief Executive Officer, will present at the Canaccord Genuity 44^th Annual Growth Conference, to take place in Boston, MA, August 14, 2024, and at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, to take place virtually, on August 15, 2024.

Event:	Canaccord Genuity 44th Annual Growth Conference
Location:	Boston, MA
Presenter:	Dr. George Magrath
Date:	August 14, 2024
Time:	9:00 a.m. ET
Format:	Fireside Chat

Event:	H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Location:	Virtual
Presenter:	Dr. George Magrath
Date:	August 15, 2024
Time:	10:30 a.m. ET
Format:	Presentation

Company management will also be available for one-on-one meetings throughout the conferences. If you are interested in arranging a meeting, please contact your conference representative or send an email to ir@ocuphire.com.

About Ocuphire Pharma

Ocuphire Pharma, Inc. (Nasdaq: OCUP) is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing novel therapies for the treatment of patients with retinal and refractive eye disorders. Ocuphire’s lead product candidate, APX3330, a novel small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein), is in development for diabetic retinopathy. In addition, Ocuphire’s late-stage product candidate Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, is being developed for presbyopia and dim (mesopic) light vision disturbances and is currently approved and marketed by our partner as RYZUMVI™ for reversal of pharmacologically induced mydriasis. For more information, please visit www.ocuphire.com. 

Contacts

Corporate	Investor Relations
Nirav Jhaveri, M.B.A. CFO ir@ocuphire.com	Corey Davis, Ph.D.  LifeSci Advisors  cdavis@lifesciadvisors.com

FAQ

When and where will Ocuphire Pharma (OCUP) present at the Canaccord Genuity conference?

Ocuphire Pharma (OCUP) will present at the Canaccord Genuity 44th Annual Growth Conference in Boston, MA on August 14, 2024, at 9:00 a.m. ET.

What is the format of Ocuphire Pharma's (OCUP) presentation at the Canaccord Genuity conference?

Ocuphire Pharma's (OCUP) presentation at the Canaccord Genuity conference will be in a fireside chat format.

When is Ocuphire Pharma (OCUP) scheduled to present at the H.C. Wainwright conference?

Ocuphire Pharma (OCUP) is scheduled to present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024, at 10:30 a.m. ET.

Who will be presenting on behalf of Ocuphire Pharma (OCUP) at these investor conferences?

Dr. George Magrath, the Chief Executive Officer of Ocuphire Pharma (OCUP), will be presenting at both investor conferences.

How can investors arrange meetings with Ocuphire Pharma (OCUP) management during these conferences?

Investors can arrange meetings with Ocuphire Pharma (OCUP) management by contacting their conference representative or sending an email to ir@ocuphire.com.